NCT06947226

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

A Phase Ib/ll Clinical Study of Safety and Efficacy of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 188 (estimated)
• Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	9MW2821	Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
DRUG	Other anti-cancer therapy	Subjects will receive other anticancer therapy as per protocol

Timeline

• Start date: 2025-04-01
• Primary completion: 2026-04-01
• Completion: 2027-04-01
• First posted: 2025-04-27
• Last updated: 2025-04-27

Locations

1 site across 1 country: China